Symposium Schedule
Morning Session
9:00-9:10 Welcome: Steve Martin; Introduction: Ellen Robey
Chair: David Raulet
9:10-9:45 MAX KRUMMEL, University of California, San Francisco
“Defining the Path from Tumor Antigens to T cell Tolerance"
9:45-10:20 BOB SCHREIBER, Washington University, St. Louis
"Cancer Immunoediting: Underlying Mechanisms and Therapeutic Implications”
10:20-10:50 BREAK (refreshments provided)
10:50-11:25 DAVID RAULET, University of California, Berkeley
"How innate mechanisms enable killer cells to detect cancer cells"
11:25-12:00 PHIL GREENBERG, University of Washington, Seattle
"Engineering cells for tumor therapy: Getting T cells all dressed up and ready to kill"
12:00-1:30 LUNCH BREAK
Afternoon Session
1:30-1:40 Chair: Mark Schlissel
1:40-2:15 JIM ALLISON, Memorial Sloan-¬‐Kettering Cancer Center, NY, New York
"Immune Checkpoint Blockade: New Insights and Opportunities"
2:15-2:50 PADMANEE SHARMA, University of Texas MD Anderson Cancer Center, Houston, Texas
"Investigating the ICOS/ICOSL pathway as a target to improve anti-¬‐CTLA-¬ ‐4 therapy"
2:50-3:20 BREAK (refreshments provided)
3:20-3:55 JEDD WOLCHOK, Memorial Sloan-‐Kettering Cancer Center, NY, New York
"Ipilimumab in the Treatment of Metastatic Melanoma: Proof of Principle for Checkpoint Blockade"
3:55-4:30 GLENN DRANOFF, Dana-Farber Cancer Institute, Boston, Massachusetts
"Mechanisms of Protective Tumor Immunity"
4:30-4:40 CLOSING REMARKS
4:40-5:40 RECEPTION (refreshments provided)